Myriad Genetics, Inc’s filing revealed that its President and CEO DIAZ PAUL J unloaded Company’s shares for reported $0.34 million on Oct 11 ’24. In the deal valued at $22.93 per share,15,000 shares were sold. As a result of this transaction, DIAZ PAUL J now holds 962,378 shares worth roughly $9.53 million.
Then, DIAZ PAUL J bought 15,000 shares, generating $343,950 in total proceeds.
Before that, Ancona Margaret bought 11,538 shares. Myriad Genetics, Inc shares valued at $321,019 were divested by the Officer at a price of $27.82 per share.
Piper Sandler upgraded its Myriad Genetics, Inc [MYGN] rating to an Overweight from a a Neutral in a research note published on March 12, 2025; the price target was increased to $12.50 from $11.50. A number of analysts have revised their coverage, including Craig Hallum’s analysts, who began to cover the stock in mid February with a ‘”a Buy”‘ rating. UBS began covering MYGN with “Neutral” recommendation on December 10, 2024. Leerink Partners revised its rating on December 09, 2024. It rated MYGN as “a Market perform” which previously was an “an Outperform”.
Price Performance Review of MYGN
On Tuesday, Myriad Genetics, Inc [NASDAQ:MYGN] saw its stock fall -2.17% to $9.90. Over the last five days, the stock has lost -3.41%. Myriad Genetics, Inc shares have fallen nearly -27.79% since the year began. Nevertheless, the stocks have fallen -53.56% over the past one year. While a 52-week high of $29.30 was reached on 02/19/25, a 52-week low of $9.36 was recorded on 03/10/25. SMA at 50 days reached $12.43, while 200 days put it at $20.19.
Levels Of Support And Resistance For MYGN Stock
The 24-hour chart illustrates a support level at 9.75, which if violated will result in even more drops to 9.59. On the upside, there is a resistance level at 10.03. A further resistance level may holdings at 10.15. The Relative Strength Index (RSI) on the 14-day chart is 35.21, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.23, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 76.33%. Stochastics %K at 26.00% indicates the stock is a holding.
How much short interest is there in Myriad Genetics, Inc?
A steep rise in short interest was recorded in Myriad Genetics, Inc stocks on 2025-02-28, growing by 46829.0 shares to a total of 4.91 million shares. Yahoo Finance data shows the prior-month short interest on 2025-01-31 was 4.86 million shares. There was a rise of 0.95%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on September 19, 2024 when Morgan Stanley began covering the stock and recommended ‘”an Equal-weight”‘ rating along with a $32 price target.
